AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9881518
Drug: Selenium enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium enriched yeast (4.8 mg containing 5 microg selenium daily via nasogastric drip during the first 14 postnatal days)
Trial: 2484663
Drug: Pirbuterol 0.2
RxNorm normalized name: pirbuterol 0.2 mg/inh inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirbuterol 0.2 mg
Trial: 2484663
Drug: Metaproterenol 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol 1.3 mg
Trial: 22293363
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 4,000 IU daily for 12 weeks
Trial: 20197426
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the dose of ICS
Trial: 20197426
Drug: Adding a
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding a leukotriene-receptor antagonist to the ICS
Trial: 20197426
Drug: Adding a
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding a long-acting beta-agonist to the ICS
Trial: 1823147
Drug: Oral selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selenium plus copper associated with vitamin complex (tocopherol and retinol)
Trial: 6860416
Drug: Once-daily tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tobramycin dosing
Trial: 6860416
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of gentamicin, tobramycin, or netilmicin
Trial: 6860416
Drug: Continuous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous tobramycin dosing
Trial: 21131037
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg infusion every 3-4 weeks)
Trial: 21131037
Drug: Clodronic acid
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronic acid (1600 mg oral daily)
Trial: 17627194
Drug: Reiki touch
RxNorm normalized name: benzethonium chloride Medicated Liquid Soap [Lysol Healthy Touch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reiki touch therapy
Trial: 15760966
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin) 0.5 mg s.c.
Trial: 1934552
Drug: Ear-canal magnets
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear-canal magnets treatment
Trial: 12760406
Drug: Tobramycin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 2.5 mg/kg/12 hr for a mean of 8 days
Trial: 12760406
Drug: Gentamicin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 2.5 mg/kg/12 hr for a mean of 8 days
Trial: 28576354
Drug: In-line intravenous
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-line intravenous fluid warming
Trial: 21261988
Drug: Health education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health education intervention based on WHO's IMCI, consisting of eight monthly 30-minute sessions.
Trial: 19050692
Drug: Trans-rectal ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-rectal ultrasound (TRUS) for biopsy
Trial: 17215658
Drug: HCTZ 50
RxNorm normalized name: HCTZ 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 50 mg/d
Trial: 17215658
Drug: HCTZ 25
RxNorm normalized name: HCTZ 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg/d
Trial: 17215658
Drug: OM 40
RxNorm normalized name: Aptiom 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM 40 mg/d (monotherapy)
Trial: 14713367
Drug: sho‐saiko‐to (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sho‐saiko‐to (2.5 g twice daily for five days)
Trial: 10084580
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (rhGH) and oxandrolone (OX) in combination
Trial: 7552095
Drug: Daily calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily calcitriol administration
Trial: 7552095
Drug: Intermittent calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent calcitriol administration
Trial: 7552095
Drug: Physiologic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic dosing of calcitriol
Trial: 7552095
Drug: Pharmacologic dosing
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic dosing of calcitriol
Trial: 2048803
Drug: Smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking intervention program and prescription of an inhaled bronchodilator
Trial: 22345878
Drug: Acamprosate 333
RxNorm normalized name: acamprosate 333 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 333 mg TDS
Trial: 20423242
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg estradiol vaginal tablets
Trial: 20423242
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg estradiol vaginal tablets
Trial: 20423242
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 10 microg and 25 microg doses
Trial: 18675392
Drug: Progressive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive and supervised 21-week concurrent strength and endurance training
Trial: 12637127
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol dry powder 12 microg BID
Trial: 11036957
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy (5‐fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7)
Trial: 11036957
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (systemic chemotherapy only)
Trial: 11036957
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy
Trial: 1325176
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose natural interferon alfa (nIFN‐alpha)
Trial: 1325176
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (CAP)
Trial: 1325176
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no maintenance treatment)
Trial: 6151145
Drug: Ceruletide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceruletide (40 micrograms, intramuscularly, twice for 2 consecutive weeks)
Trial: 21786162
Drug: Hay +
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hay + 150 g moringa leaf (T2)
Trial: 21786162
Drug: Hay +
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hay + 300 g moringa leaf (T3)
Trial: 21786162
Drug: Hay +
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hay + 450 g moringa leaf (T4)
Trial: 12583554
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid (2.2 g) and Cefazolin (2 g)
Trial: 10626237
Drug: Clofazimine 50
RxNorm normalized name: clofazimine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 50 mg daily for six months in addition to the WHO regimen
Trial: 10626237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard WHO regimen (six doses of once a month rifampicin with daily dapsone for six months)
Trial: 3636818
Drug: Z‐track intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z‐track intramuscular injection technique
Trial: 27101668
Drug: Nasal endoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal endoscope negative pressure cleaning and normal saline spray washing
Trial: 22043464
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (5 to 8.5 mm)
Trial: 22043464
Drug: Bone augmentation
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone augmentation with autogenous bone for longer implants (>11.5 mm)
Trial: 22043464
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (short implants and augmented longer implants)
Trial: 19916291
Drug: Medication with
RxNorm normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication with Omeperazole (20 mg, qd.)
Trial: 11297595
Drug: Troglitazone 300
RxNorm normalized name: troglitazone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 300 mg/day (TGZ-300)
Trial: 11297595
Drug: Troglitazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 600 mg/day (TGZ-600)
Trial: 9508155
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with chlorthalidone (12.5-25 mg/d)
Trial: 8070930
Drug: Ampicillin/sulbactam (33.3/16.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (33.3/16.7 mg/kg bodyweight)
Trial: 27580827
Drug: Social facilitation
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social facilitation maintenance treatment (4 months, 16 outpatient group sessions)
Trial: 27580827
Drug: Social facilitation
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social facilitation maintenance treatment
Trial: 21736587
Drug: Robenacoxib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 5 mg/kg once daily for 28 days
Trial: 21736587
Drug: Robenacoxib 10
RxNorm normalized name: robenacoxib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 10 mg/kg once daily for 28 days
Trial: 21736587
Drug: Robenacoxib 2
RxNorm normalized name: robenacoxib 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 2 mg/kg twice daily for 42 days
Trial: 21736587
Drug: Robenacoxib 6
RxNorm normalized name: robenacoxib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 6 mg/kg twice daily for 42 days
Trial: 21736587
Drug: Robenacoxib 10
RxNorm normalized name: robenacoxib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robenacoxib 10 mg/kg twice daily for 42 days
Trial: 18498919
Drug: Carvedilol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (0.4 mg/kg/d in children <or=62.5 kg or 25 mg/d in children >62.5 kg)
Trial: 12825804
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Dalteparin 2 x 5,000U)
Trial: 12825804
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (UFH) (5,000U bolus followed by infusion to raise APTT to 1.5 times control)
Trial: 23349309
Drug: Post-remission chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-remission chemotherapy
Trial: 21315644
Drug: Induction chemoradiation
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemoradiation (60 Gy, 2 Gy/fraction; concomitant 5‐fluoro‐uracil infusion, 300 mg/m(2) per day, days 1‐5 for 6 weeks; cisplatin, 20 mg/m(2) per day, days 1‐5 during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Trial: 21315644
Drug: Induction gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction gemcitabine (1000 mg/m(2) weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Trial: 19827653
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Control group, n = 47)
Trial: 18261273
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (20 ml once a day for 15 days)
Trial: 18261273
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg once a day for 15 days)
Trial: 15238591
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (weight-adjusted intravenous)
Trial: 9674293
Drug: Enalapril up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril up to 20 mg/day
Trial: 3393620
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and exposure therapy
Trial: 3393620
Drug: Imipramine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine and exposure therapy
Trial: 27614675
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid-based parenteral nutrition (Omegaven, Fresenius-Kabi, Germany) for 5 days postoperatively
Trial: 23168119
Drug: Per oral
RxNorm normalized name: Amino Acids/Copper Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral endoscopic myotomy
Trial: 12161101
Drug: rhGM-CSF 5
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhGM-CSF 5 mcg/kg/d for 4 days, IV
Trial: 12161101
Drug: rhG-CSF 10
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhG-CSF 10 mcg/kg/d for 4 days, IV
Trial: 9527776
Drug: P‐HTIG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐HTIG plus Td vaccine
Trial: 7637157
Drug: Oral triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral triazolam (0.25 mg)
Trial: 7637157
Drug: Oral tizanidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tizanidine (3 mg)
Trial: 27633135
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) consumption, 200 ml daily for six weeks
Trial: 25875324
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment group receiving business training, $150, and supervision and advising.
Trial: 19436135
Drug: Light resistance
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light resistance exercise (15 min dumbbell exercise using 300 g brown‐rice‐filled fabric dumbbells)
Trial: 15187817
Drug: Hypoglycaemia (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycaemia (up to 69 mg/dl)
Trial: 15187817
Drug: Euglycaemic (80-109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemic (80-109 mg/dl)
Trial: 15187817
Drug: Diabetic (>140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic (>140 mg/dl)
Trial: 15187817
Drug: Low normal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low normal (70-79 mg/dl)
Trial: 15187817
Drug: Borderline diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Borderline diabetics (126-139 mg/dl)
Trial: 15187817
Drug: Impaired fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired fasting glucose (110-125 mg/dl)
Trial: 11209624
Drug: Elective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective treatment cohort design with randomization
Trial: 9440631
Drug: One-week course
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine
Trial: 9440631
Drug: Six-week course
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six-week course of ranitidine 300 mg/day
Trial: 8517902
Drug: Heparin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (0.25 U/ml)
Trial: 3683021
Drug: Oxaprozin 600
RxNorm normalized name: oxaprozin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaprozin 600 mg
Trial: 3683021
Drug: Oxaprozin 1200
RxNorm normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaprozin 1200 mg
Trial: 27344212
Drug: Heparin‐coated dialyzers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐coated dialyzers
Trial: 7572630
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin alone (Control group, n = 35)
Trial: 7572630
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous nitroglycerin and heparin (n = 31)
Trial: 7572630
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous isosorbide dinitrate and heparin (n = 30)
Trial: 6119025
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving outpatient clinic treatment for high GGT levels
Trial: 31562049
Drug: Mold-fermented cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mold-fermented cheese (MFC) 33.4 g daily for 3 months
Trial: 31562049
Drug: Non-MFC (processed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MFC (processed cheese made from mozzarella cheese and cream cheese) 33.4 g daily for 3 months
Trial: 26167086
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg/d) monotherapy
Trial: 24506429
Drug: Protease Inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease Inhibitor (PI) or Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Trial: 21980934
Drug: Ultra-rush grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-rush grass pollen immunotherapy with sublingual drops (Staloral)®
Trial: 19095776
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to treatment failure
Trial: 19095776
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of trials using PFS, TTP, or time to treatment failure vs. RR
Trial: 16893378
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg d(‐1))
Trial: 16893378
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg d(‐1))
Trial: 10385063
Drug: Calcitriol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.5 mg twice per day)
Trial: 30393209
Drug: CartiNovex plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CartiNovex plus tablet
Trial: 21933229
Drug: PM103 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM103 (0.1, 1.0, 10, 30, 100 or 300 mg)
Trial: 20668354
Drug: Irbesartan plus
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan plus amiodarone (irbesartan 150 mg/d, n=43)
Trial: 17111172
Drug: Flupentixol (FLX)
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol (FLX) 5.7 +/- 1.4 mg/day
Trial: 17111172
Drug: Haloperidol (HAL)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (HAL) 8.5 +/- 5.5 mg/day
Trial: 17111172
Drug: Risperidone (RIS)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone (RIS) 3.6 +/- 1.3 mg/day
Trial: 23582153
Drug: Histamine H1-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H1-receptor antagonists
Trial: 23582153
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of stimulation at 90 seconds
Trial: 19846743
Drug: Androgen replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen replacement therapy (ART) with 1.5 mg methyl testosterone for 1 year
Trial: 17043732
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate 885 mg/day for 2 weeks (Group III)
Trial: 17043732
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (all groups)